Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463070 | 0.87 | ADRA1D (0.51) | CCR2ADRA1D | |
| SCHEMBL5450089 | 0.82 | CCR2 (0.63) | CCR2SLC2A1ADRA1D | |
| SCHEMBL14386890 | 0.78 | CCR2 (0.77) | CCR2 | |
| SCHEMBL5358213 | 0.78 | CCR2 (0.53) | CCR2SLC2A1 | |
| SCHEMBL14387068 | 0.77 | CCR2 (0.78) | CCR2SLC2A1 | |
| SCHEMBL5358216 | 0.77 | CCR2 (0.78) | CCR2SLC2A1 | |
| SCHEMBL5331458 | 0.77 | HTR2C (0.57) | CCR2ADRA1D | |
| SCHEMBL5328673 | 0.75 | KDM4E (0.51) | CCR2 | |
| SCHEMBL5327055 | 0.75 | KDM4E (0.56) | CCR2 | |
| SCHEMBL5328670 | 0.75 | KDM4E (0.55) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | CCR2 1/4885SLC2A1 2264/4885ADRA1D 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.